Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2006-07-25
2006-07-25
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S562000, C560S115000, C560S157000, C560S222000, C562S506000
Reexamination Certificate
active
07081481
ABSTRACT:
Compounds of the formula (I) in which: R1is (CH2)nY; n is 1 or 2; Y is NHSO2R2or X1—W—X2—R3; X1is O or NH; W is C═O, C═S, C═NH, or SO2; X2is O or NH, provided that X1and X2are not both O; R2is C1-10alkyl; C2-10alkenyl; C2-10alkynyl; aryl; aryl-C1-10alkyl; aryl-C2-10alkenyl; aryl-C2-10alkynyl; C3-8cycloalkyl or C3-8-cycloalkyl-C1-10alkyl; and R3is hydrogen, C1-10alkyl; C2-10alkenyl; C2-10alkynyl; aryl; aryl-C1-10alkyl; aryl-C2-10alkenyl; aryl-C2-10alkynyl; C3-8cycloalkyl; or C3-8-cycloalkyl-C1-10alkyl; or a salt or ester thereof, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system.
REFERENCES:
patent: 6172058 (2001-01-01), Tercero et al.
patent: 6498180 (2002-12-01), Collado et al.
patent: 6504052 (2003-01-01), Collado et al.
patent: 0 870 760 (1998-10-01), None
patent: WO 01/92212 (2001-12-01), None
Baskys et al., Understanding regulation of nerve cell death by mGluRs as a method for development of successful neuroprotective strategies, Journal of the Neurological Sciences 229-230 (2005) 201-209.
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the internet, URL; http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html>.
Pellicciari et al: “Synthesis and Pharmacological Characterization of All Sixteen Stereoisomers of 2-(2′-Carboxy-3′-phenylcyclopropyl)glycine . Focus on (2S, I'S,2'S,3'R)-2-(2′-Carboxy-3′-phenylcy clopropyl)glycine, a Novel and Selective Group II Metabotropic Glutamate Receptor Antagonist” Journal of Medicinal Chemistry, American Chemical Society. Washington, US, vol. 39, No. 11, 1996, pp. 2259-2269, XP002122695 ISSN: 0022-2623 cited in the application pp. 2259-2269.
Collado, Ivan et A., (2S,1'S,2′ R,3′R)-2-(2′-Carboxy-3′-hydroxymethylcyclopropyl) Glycine Is a Highly Potent Group 2 and 3 Metabotropic Glutamate Receptor Agonist with Oral Activity, J. Med. Chem, 2004, 456-466, vol. 47.
Johnson, Byran G. et al, [2H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate {mGlu} receptors: characterization of binding to membranes of mGlu receptors subtype expressing cells, Neuropharmacology, 1999, 1519-1529 vol. 38.
Collado-Cano Ivan
De Uralde-Garmendia Beatriz López
Gonzalez-Garcia Maria Rosario
Anderson Arvie J.
Anderson Rebecca
Eli Lilly and Company
Saeed Kamal A.
Winter Mark A.
LandOfFree
Excitatory amino acid receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Excitatory amino acid receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Excitatory amino acid receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3543008